Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
648 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Melanoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2016', provides an overview of the Metastatic Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma - The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects - The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Metastatic Melanoma Overview 8 Therapeutics Development 9 Metastatic Melanoma - Therapeutics under Development by Companies 11 Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Melanoma - Pipeline Products Glance 19 Metastatic Melanoma - Products under Development by Companies 22 Metastatic Melanoma - Products under Investigation by Universities/Institutes 30 Metastatic Melanoma - Companies Involved in Therapeutics Development 31 Metastatic Melanoma - Therapeutics Assessment 113 Drug Profiles 137 Metastatic Melanoma - Dormant Projects 601 Metastatic Melanoma - Discontinued Products 615 Metastatic Melanoma - Product Development Milestones 617 Appendix 631
List of Tables
Number of Products under Development for Metastatic Melanoma, H2 2016 25 Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016 26 Number of Products under Development by Companies, H2 2016 27 Number of Products under Development by Companies, H2 2016 (Contd..1) 28 Number of Products under Development by Companies, H2 2016 (Contd..2) 29 Number of Products under Development by Companies, H2 2016 (Contd..3) 30 Number of Products under Development by Companies, H2 2016 (Contd..4) 31 Number of Products under Development by Companies, H2 2016 (Contd..5) 32 Number of Products under Investigation by Universities/Institutes, H2 2016 34 Comparative Analysis by Late Stage Development, H2 2016 35 Comparative Analysis by Clinical Stage Development, H2 2016 36 Comparative Analysis by Early Stage Development, H2 2016 37 Products under Development by Companies, H2 2016 38 Products under Development by Companies, H2 2016 (Contd..1) 39 Products under Development by Companies, H2 2016 (Contd..2) 40 Products under Development by Companies, H2 2016 (Contd..3) 41 Products under Development by Companies, H2 2016 (Contd..4) 42 Products under Development by Companies, H2 2016 (Contd..5) 43 Products under Development by Companies, H2 2016 (Contd..6) 44 Products under Development by Companies, H2 2016 (Contd..7) 45 Products under Investigation by Universities/Institutes, H2 2016 46 Metastatic Melanoma - Pipeline by AB Science SA, H2 2016 47 Metastatic Melanoma - Pipeline by AbbVie Inc, H2 2016 48 Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 49 Metastatic Melanoma - Pipeline by Affichem SA, H2 2016 50 Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2016 51 Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H2 2016 52 Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H2 2016 53 Metastatic Melanoma - Pipeline by Amgen Inc., H2 2016 54 Metastatic Melanoma - Pipeline by Angimmune LLC, H2 2016 55 Metastatic Melanoma - Pipeline by Apexigen, Inc., H2 2016 56 Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 57 Metastatic Melanoma - Pipeline by Array BioPharma Inc., H2 2016 58 Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 59 Metastatic Melanoma - Pipeline by AstraZeneca Plc, H2 2016 60 Metastatic Melanoma - Pipeline by Basilea Pharmaceutica Ltd., H2 2016 61 Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 62 Metastatic Melanoma - Pipeline by BerGenBio AS, H2 2016 63 Metastatic Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016 64 Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2016 65 Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 66 Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 67 Metastatic Melanoma - Pipeline by Calithera Biosciences, Inc., H2 2016 68 Metastatic Melanoma - Pipeline by Cellceutix Corporation, H2 2016 69 Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 70 Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H2 2016 71 Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2016 72 Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2016 73 Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2016 74 Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2016 75 Metastatic Melanoma - Pipeline by Eli Lilly and Company, H2 2016 76 Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H2 2016 77 Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 78 Metastatic Melanoma - Pipeline by Galapagos NV, H2 2016 79 Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2016 80 Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016 81 Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 82 Metastatic Melanoma - Pipeline by Ignyta, Inc., H2 2016 83 Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2016 84 Metastatic Melanoma - Pipeline by Immunocore Limited, H2 2016 85 Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2016 86 Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2016 87 Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 88 Metastatic Melanoma - Pipeline by IO Biotech ApS, H2 2016 89 Metastatic Melanoma - Pipeline by Lentigen Technology, Inc., H2 2016 90 Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2016 91 Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2016 92 Metastatic Melanoma - Pipeline by MacroGenics, Inc., H2 2016 93 Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2016 94 Metastatic Melanoma - Pipeline by Medivation, Inc., H2 2016 95 Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H2 2016 96 Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2016 97 Metastatic Melanoma - Pipeline by Merck KGaA, H2 2016 98 Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 99 Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H2 2016 100 Metastatic Melanoma - Pipeline by Moleculin Biotech Inc, H2 2016 101 Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2016 102 Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H2 2016 103 Metastatic Melanoma - Pipeline by Novartis AG, H2 2016 104 Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2016 105 Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2016 106 Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H2 2016 107 Metastatic Melanoma - Pipeline by Onxeo SA, H2 2016 108 Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2016 109 Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H2 2016 110 Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2016 111 Metastatic Melanoma - Pipeline by PinCell srl, H2 2016 112 Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2016 113 Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 114 Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H2 2016 115 Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 116 Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H2 2016 117 Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 118 Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H2 2016 119 Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 120 Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2016 121 Metastatic Melanoma - Pipeline by Sillajen Biotherapeutics, H2 2016 122 Metastatic Melanoma - Pipeline by SolaranRx, Inc., H2 2016 123 Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 124 Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2016 125 Metastatic Melanoma - Pipeline by TC BioPharm Limited, H2 2016 126 Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H2 2016 127 Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2016 128 Assessment by Monotherapy Products, H2 2016 129 Assessment by Combination Products, H2 2016 130 Number of Products by Stage and Target, H2 2016 132 Number of Products by Stage and Mechanism of Action, H2 2016 141 Number of Products by Stage and Route of Administration, H2 2016 150 Number of Products by Stage and Molecule Type, H2 2016 152 Metastatic Melanoma - Dormant Projects, H2 2016 617 Metastatic Melanoma - Dormant Projects (Contd..1), H2 2016 618 Metastatic Melanoma - Dormant Projects (Contd..2), H2 2016 619 Metastatic Melanoma - Dormant Projects (Contd..3), H2 2016 620 Metastatic Melanoma - Dormant Projects (Contd..4), H2 2016 621 Metastatic Melanoma - Dormant Projects (Contd..5), H2 2016 622 Metastatic Melanoma - Dormant Projects (Contd..6), H2 2016 623 Metastatic Melanoma - Dormant Projects (Contd..7), H2 2016 624 Metastatic Melanoma - Dormant Projects (Contd..8), H2 2016 625 Metastatic Melanoma - Dormant Projects (Contd..9), H2 2016 626 Metastatic Melanoma - Dormant Projects (Contd..10), H2 2016 627 Metastatic Melanoma - Dormant Projects (Contd..11), H2 2016 628 Metastatic Melanoma - Dormant Projects (Contd..12), H2 2016 629 Metastatic Melanoma - Dormant Projects (Contd..13), H2 2016 630 Metastatic Melanoma - Discontinued Products, H2 2016 631 Metastatic Melanoma - Discontinued Products (Contd..1), H2 2016 632
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
